We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.61%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.64B
AUM Growth
-$358M
Cap. Flow
-$561M
Cap. Flow %
-15.41%
Top 10 Hldgs %
62.29%
Holding
72
New
2
Increased
4
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$77M
2
TYRA icon
Tyra Biosciences
TYRA
+$31.5M
3
ALLK
Allakos
ALLK
+$12.4M
4
IMUX icon
Immunic
IMUX
+$11.6M
5
UNCY icon
Unicycive Therapeutics
UNCY
+$1.81M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$158M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$69.8M
3
MRUS
Merus
MRUS
+$64.1M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$54.1M
5
KURA icon
Kura Oncology
KURA
+$50.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THRD
26
DELISTED
Third Harmonic Bio
THRD
$41.2M 1.13%
4,365,933
– –
ENGN icon
27
enGene Therapeutics
ENGN
$117M
$38.2M 1.05%
2,251,037
– –
NAMS icon
28
NewAmsterdam Pharma
NAMS
$3.22B
$36M 0.99%
1,521,948
– –
GPCR icon
29
Structure Therapeutics
GPCR
$3.34B
$34.8M 0.96%
812,988
– –
ROIV icon
30
Roivant Sciences
ROIV
$24.3B
$28.9M 0.79%
2,742,409
– –
CBIO
31
Crescent Biopharma
CBIO
$519M
$28.6M 0.79%
95,443
– –
TCRX icon
32
TScan Therapeutics
TCRX
$48.6M
$23.7M 0.65%
2,989,474
– –
ALLK
33
DELISTED
Allakos
ALLK
$20.9M 0.57%
16,552,417
+8,000,000
+94% +$12.4M
VSTM icon
34
Verastem
VSTM
$489M
$19.9M 0.55%
1,685,219
– –
CALT
35
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$16.2M 0.45%
750,000
– –
CTMX icon
36
CytomX Therapeutics
CTMX
$684M
$14.4M 0.4%
6,595,801
– –
ELEV
37
DELISTED
Elevation Oncology
ELEV
$11.9M 0.33%
2,312,200
– –
OVID icon
38
Ovid Therapeutics
OVID
$416M
$11.8M 0.32%
3,853,818
-2,997,233
-44% -$10M
IMUX icon
39
Immunic
IMUX
$187M
$11.8M 0.32%
+890,297
New +$11.6M
VTGN icon
40
VistaGen Therapeutics
VTGN
$10M
$10.6M 0.29%
2,000,000
– –
ELDN icon
41
Eledon Pharmaceuticals
ELDN
$259M
$8.91M 0.25%
4,326,710
– –
VERV
42
DELISTED
Verve Therapeutics
VERV
$8.63M 0.24%
650,000
– –
IMA
43
ImageneBio Inc
IMA
$62.9M
$6.77M 0.19%
397,430
– –
CDTX
44
DELISTED
Cidara Therapeutics
CDTX
$6.31M 0.17%
343,056
– –
VIGL
45
DELISTED
Vigil Neuroscience
VIGL
$6.18M 0.17%
1,813,633
– –
DCTH icon
46
Delcath Systems
DCTH
$411M
$5.73M 0.16%
1,202,067
+225,918
+23% +$975K
UNCY icon
47
Unicycive Therapeutics
UNCY
$137M
$4.98M 0.14%
361,160
+149,346
+71% +$1.81M
ENGNW icon
48
enGene Therapeutics Warrants
ENGNW
$3.64M
$4.92M 0.14%
945,402
– –
SABS icon
49
SAB Biotherapeutics
SABS
$267M
$4.17M 0.11%
917,826
-2
-0% -$11
LXRX icon
50
Lexicon Pharmaceuticals
LXRX
$1.03B
$4.05M 0.11%
1,686,924
-22,748,708
-93% -$48.9M
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2024 Portfolio in Review

As of Q1 2024, BVF Inc held 72 positions worth $3.64B, down 9% from $4B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc withdrew a net $561M in Q1 2024, closing 10 positions and reducing 13 holdings. Its most notable exit was Axsome Therapeutics, an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in CG Oncology worth $82.7M.

  • BVF Inc's largest Q1 2024 buy was CG Oncology: 1,884,191 shares worth $82.7M.
  • BVF Inc added most to Tyra Biosciences in Q1 2024, an estimated $31.5M increase.
  • BVF Inc's biggest Q1 2024 reduction was Merus, cutting an estimated $64.1M.
  • BVF Inc fully exited Axsome Therapeutics in Q1 2024, selling an estimated $158M.
  • BVF Inc's ten largest holdings make up 62% of its $3.64B portfolio in Q1 2024.
  • BVF Inc opened 2 new positions and closed 10 in Q1 2024.
  • BVF Inc's portfolio value fell 9% quarter-over-quarter to $3.64B.

Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.